Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel medicine application of torasemide

A new use technology of torasemide, which is applied in the field of new drug use of torasemide, can solve the problems that heart failure cannot be reversed, and treatment can only be delayed.

Inactive Publication Date: 2016-12-07
NANJING ZENKOM PHARMA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The drug treatment of cardiac hypertrophy is to treat the disease by blocking the signal pathway, such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc., but the treatment can only delay, not reverse the process of heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel medicine application of torasemide
  • Novel medicine application of torasemide
  • Novel medicine application of torasemide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The applicant applied Examples 1-6 of patent 201610481309.6 to 200 patients with cardiac hypertrophy, and conducted follow-up observations for 4 weeks.

[0014] 1. Clinical data

[0015] (1) General Information

[0016] The cases came from three hospitals in this city. From January 2015 to February 2016, 200 patients with cardiac hypertrophy were treated, including 112 males and 88 females, aged 31-72 years, with an average age of 62.65 years, of which 29 cases were 31-40 years old. 88 cases aged 40 to 65, and 83 cases aged 65 to 72 were randomly divided into a treatment group of 100 cases and a control group of 100 cases according to medical history and etiology of cardiac hypertrophy, and there was no significant difference in general data between the two groups (P>0.05 ), which are comparable. All patients were excluded: ① Refractory hypertension or hypotension; ② History of alcohol or drug abuse; ③ Pregnant or lactating women; ④ Severe lung disease.

[0017] (2) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel medicine application of torasemide. The torasemide can inhibit cardiomegaly caused by high blood pressure, heart failure, myocardial fibrosis, myocarditis and the like. A small dosage of torasemide or injection can obviously improve cardiomegaly.

Description

technical field [0001] The invention relates to a new medicine application of torasemide. Background technique [0002] Cardiac hypertrophy is the increase in heart weight caused by sustained pressure or volume overload, and can be divided into physiological hypertrophy and pathological hypertrophy. Physiological hypertrophy is generally caused by a large amount of aerobic exercise or pregnancy. It is a benign adaptation of the myocardium to stress. The changes in cardiac morphology are mainly manifested by hypertrophy of the posterior wall of the ventricle and the interventricular septum. Physiological hypertrophy is considered to be beneficial. Pathological hypertrophy is the compensatory response of the heart to various stimuli in order to maintain the cardiac output, but the long-term overload of the heart will not only cause the disorder of the diastolic function of the heart, but also lead to the failure of heart filling and ischemic heart disease. , arrhythmia, sudde...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/44A61P9/12A61P9/04A61P9/00
CPCA61K31/44
Inventor 单飞徐卓业
Owner NANJING ZENKOM PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com